Lenus Health to participate in Slush 2022
The carbon-negative event will take place in Helsinki, Finland with more than 12,000 attendees making it the world’s largest cross industry startup - investor network
Lenus Health will join Slush 2022 in conjunction with AstraZeneca to showcase how data and artificial intelligence are being used to transform the diagnosis and management of long-term conditions such as heart failure and chronic obstructive pulmonary disease (COPD). The carbon-negative event will take place in Helsinki, Finland on the 17th and 18th of November with more than 12,000 attendees making it the world’s largest cross industry startup - investor network.
Lenus Health recently joined AstraZeneca UK as the exclusive digital partner in a landmark Memorandum of Understanding (MOU) to co-create NHS Scotland transformation through large scale programmes to improve the health of the population and expand clinical research.
As a global partner of Slush, AstraZeneca’s A.Catalyst Network will be supporting the event to drive further progress in healthcare and maximise opportunities with new innovators to expand access and ensure better outcomes for patients all around the globe.
A comprehensive schedule of talks and side events will be hosted on the AstraZeneca A.Catalyst Network booth. Attendees interested in understanding the impact and potential of structured datasets used to enable proactive and personalised care can join Lenus Health co-founder and CEO, Paul McGinness, there at the Healthcare Innovators Lounge:
- Thursday, 17 November at 3pm local time for “I came, I saw but how do I conquer?” where he will share his 20 years’ experience in public sector transformation; and
- Friday, 18 November at 1pm local time for the “Health-tech startup pitch” event featuring Lenus Health’s vision for more efficient and effective care of long-term conditions
Paul McGinness, Chief Executive Officer, Lenus Health said, “By teaming up with AstraZeneca at Slush, we are excited to share how the Lenus platform is reducing diagnostic waiting lists and costly hospital admissions with the wider start-up and investor community. We look forward to learning from others and benefiting from the global A.Catalyst Network community.”
In partnership with healthcare systems, these new patient care models will generate evidence-based practice changeBinder Fagura, AstraZeneca UK Head of External Scientific Engagement
Binder Fagura, AstraZeneca UK Head of External Scientific Engagement, also attending Slush said: “It’s a privilege to host Lenus Health at AstraZeneca’s A.Catalyst booth at Slush! Our purpose-led partnership aims to integrate chronic disease pathways to reduce waiting times and address healthcare inequity in the UK. In partnership with healthcare systems, these new patient care models will generate evidence-based practice change to enable the spread and scale of these innovative care models and most importantly, improve outcomes for patients at a population level.”
Please use the SLUSH Matchmaking tool to register for these side events featuring Lenus Health, or alternatively reach out to Paul McGinness to organise a meeting.